Advanced

The role of RANK-ligand inhibition in cancer : the story of denosumab

Castellano, Daniel; Sepulveda, Juan Manuel; García-Escobar, Ignacio; Rodriguez-Antolín, Alfredo; Sundlöv, Anna LU and Cortes-Funes, Hernán (2011) In The oncologist 16(2). p.45-136
Abstract

The diagnosis of bone metastases is an event with certain consequences for the patient. They often mean pain and can also mean pathological fractures, hypercalcemia, and spinal cord compression, all synonymous with a diminished quality of life and often also hospitalization. Since the advent of the intravenous bisphosphonates, things began to look a bit brighter for patients with bone metastases-bone destruction was kept at bay a little longer. The next generation of bone metastasis treatments is well on its way in clinical development, and among them, the most advanced drug is denosumab. Denosumab is a fully human monoclonal antibody that inhibits osteoclast maturation, activation, and function by binding to receptor activator of... (More)

The diagnosis of bone metastases is an event with certain consequences for the patient. They often mean pain and can also mean pathological fractures, hypercalcemia, and spinal cord compression, all synonymous with a diminished quality of life and often also hospitalization. Since the advent of the intravenous bisphosphonates, things began to look a bit brighter for patients with bone metastases-bone destruction was kept at bay a little longer. The next generation of bone metastasis treatments is well on its way in clinical development, and among them, the most advanced drug is denosumab. Denosumab is a fully human monoclonal antibody that inhibits osteoclast maturation, activation, and function by binding to receptor activator of nuclear factor kappa B ligand, with the final result being a reduced rate of bone resorption. In this review, we give an overview of relevant preclinical and clinical data regarding the use of denosumab in patients with solid tumors in general and prostate cancer in particular.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Bone Neoplasms, Bone Remodeling, Breast Neoplasms, Clinical Trials as Topic, Denosumab, Humans, Male, Multiple Myeloma, Osteoclasts, Prostatic Neoplasms, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B, Treatment Outcome, Journal Article, Research Support, Non-U.S. Gov't, Review
in
The oncologist
volume
16
issue
2
pages
45 - 136
external identifiers
  • scopus:79952614068
ISSN
1549-490X
DOI
10.1634/theoncologist.2010-0154
language
English
LU publication?
yes
id
5f83e8c2-14ad-4ae2-a57f-259c371876b2
date added to LUP
2017-11-16 09:58:54
date last changed
2018-08-05 04:45:57
@article{5f83e8c2-14ad-4ae2-a57f-259c371876b2,
  abstract     = {<p>The diagnosis of bone metastases is an event with certain consequences for the patient. They often mean pain and can also mean pathological fractures, hypercalcemia, and spinal cord compression, all synonymous with a diminished quality of life and often also hospitalization. Since the advent of the intravenous bisphosphonates, things began to look a bit brighter for patients with bone metastases-bone destruction was kept at bay a little longer. The next generation of bone metastasis treatments is well on its way in clinical development, and among them, the most advanced drug is denosumab. Denosumab is a fully human monoclonal antibody that inhibits osteoclast maturation, activation, and function by binding to receptor activator of nuclear factor kappa B ligand, with the final result being a reduced rate of bone resorption. In this review, we give an overview of relevant preclinical and clinical data regarding the use of denosumab in patients with solid tumors in general and prostate cancer in particular.</p>},
  author       = {Castellano, Daniel and Sepulveda, Juan Manuel and García-Escobar, Ignacio and Rodriguez-Antolín, Alfredo and Sundlöv, Anna and Cortes-Funes, Hernán},
  issn         = {1549-490X},
  keyword      = {Antibodies, Monoclonal,Antibodies, Monoclonal, Humanized,Antineoplastic Agents,Bone Neoplasms,Bone Remodeling,Breast Neoplasms,Clinical Trials as Topic,Denosumab,Humans,Male,Multiple Myeloma,Osteoclasts,Prostatic Neoplasms,RANK Ligand,Receptor Activator of Nuclear Factor-kappa B,Treatment Outcome,Journal Article,Research Support, Non-U.S. Gov't,Review},
  language     = {eng},
  number       = {2},
  pages        = {45--136},
  series       = {The oncologist},
  title        = {The role of RANK-ligand inhibition in cancer : the story of denosumab},
  url          = {http://dx.doi.org/10.1634/theoncologist.2010-0154},
  volume       = {16},
  year         = {2011},
}